# A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

> **NCT04699604** · PHASE3 · RECRUITING · sponsor: **Bridgette Jones** · enrollment: 300 (estimated)

## Conditions studied

- Allergic Asthma

## Interventions

- **DRUG:** Levocetirizine Dihydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04699604
- **Lead sponsor:** Bridgette Jones
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-28
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04699604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04699604, "A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04699604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*